APA (7th ed.) Citation

Hamilton, D. O., Main-Ian, A., Tebbutt, J., Thrasher, M., Waite, A., & Welters, I. (2021). Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19. Thrombosis Journal, 19(1), 1. https://doi.org/10.1186/s12959-021-00337-z

Chicago Style (17th ed.) Citation

Hamilton, David Oliver, Alexander Main-Ian, Jessie Tebbutt, Maya Thrasher, Alicia Waite, and Ingeborg Welters. "Standard- Versus Intermediate-dose Enoxaparin for Anti-factor Xa Guided Thromboprophylaxis in Critically Ill Patients with COVID-19." Thrombosis Journal 19, no. 1 (2021): 1. https://doi.org/10.1186/s12959-021-00337-z.

MLA (9th ed.) Citation

Hamilton, David Oliver, et al. "Standard- Versus Intermediate-dose Enoxaparin for Anti-factor Xa Guided Thromboprophylaxis in Critically Ill Patients with COVID-19." Thrombosis Journal, vol. 19, no. 1, 2021, p. 1, https://doi.org/10.1186/s12959-021-00337-z.